July 17, 2015
The market for chronic hepatitis C treatments has seen a sea of change with the advent of oral drugs that make interferon (IFN) unnecessary. In September 2014, a dual regimen of Daklinza (daclatasvir) and Sunvepra (asunaprevir) debuted in Japan ahead...read more